Personnel
Hans-Peter Hartung named coordinator for phase II/III trial of MBP8298 in multiple sclerosis
Published in Medical Device Law Weekly, December 24th, 2006
BioMS Medical Corp (MS), a developer in the treatment of multiple sclerosis (MS), announced professor Hans-Peter Hartung as National Coordinator in Germany for the ongoing pivotal phase II/III trial of its lead drug, MBP8298, a proprietary synthetic peptide for the treatment of multiple sclerosis. professor Hartung is also a member of the Clinical Advisory Group for the international phase II/III trial.
Professor Hartung is professor and chairman, Department of Neurology at Heinrich-Heine-Universitut Dusseldorf in Germany.
"Professor Hartung is world renowned in the area of multiple sclerosis and we are very pleased to have his support and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Law Weekly
More Articles from Medical Device Law Weekly
- Business & Finance
Delcath Systems issues third quarter update - Business & Finance
MedCom USA shareholders to receive shares in new subsidiary Card Activation Technologies - Business & Finance
Sontra Medical reports Q3 2006 49-cent-per-share loss, efforts to raise private capital - Business Update
IOMED reports on 2006 annual shareholders' meeting - Healthcare Costs
Society of Nuclear Medicine requests action to alter DRA provision for imaging payment caps - Information Technology
Philips announces asset tracking solution - More from this issue of Medical Device Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
